Targeted cancer missile vs. immune booster: Head-to-Head fight for myeloma control
Disease control
Not yet recruiting
This study aims to find the better initial treatment for adults newly diagnosed with multiple myeloma who are not candidates for a stem cell transplant. It will compare two different drug combinations: one featuring a targeted 'antibody-drug conjugate' (belantamab mafodotin) and …
Phase: PHASE3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC